We describe ourselves as a new breed life sciences advisory firm which operates at the nexus of innovative medicines, data & digital technology, and new business models to reimagine existing processes across the drug value chain and create new competitive advantages for our pharma, biotech and medtech customers. Our customers today work with us across drug discovery, drug-product commercialization, drug-product life cycle management, drug supply chain management, cold chain, and beyond the molecule initiatives.
The most exceptional opportunity is meaningless without a robust strategy that can be executed with precision, forming the bridge between vision and outcome. Our customers today leverage our strategic services across drug development & manufacturing, drug-product commercialization, drug-product life cycle management, cold chain, drug dispensing, and beyond the molecule initiatives.
Strategic services offered at both global and business unit level include:
The ability to embed external thinking and doing into your organization in an agile and dynamic manner is key to successful transformations and growth. At Reformulate, we can provide you with experienced senior executives who are ‘entrepreneurs in residence’ in your organization.
Our ‘entrepreneur in residence’ will form a key part of your team for a period as short or as long as needed. Services include:
As new technological paradigms mature and value propositions shift to drive long-term healthcare value and impact, it is critical that life science companies stay at the forefront of industry shifts and changes. We help clients to become and stay deeply immersed in the current state of the industry and where it is heading, allowing them to more effectively allocate resources and determine strategic priorities.
Coverage can include:
Exploring new markets and staying well versed across the development of currently penetrated markets involves performing detailed sizings of both the addressable and total market. Our market sizings provide clients with a clear view as to size of the potential opportunity or remaining growth potential, and transcend numbers to clearly illustrate the ‘so what’ and the courses of action to success.
We leverage a number of primary and secondary sources to inform the sizing including expert & KOL interviews, internal company data and external industry reports & data.
Robust opportunity assessment is critical to the identification and development of scalable solutions that enhance therapeutic area revenue across the drug value chain. As part of the assessment, several dimensions must be explored to provide an accurate view as to the attractiveness of the opportunity, including size, risks, competitor landscape & positioning, and required capabilities to execute.
combines the culture, people, strategy, go-to-market capabilities, and partnerships required to focus on the solution design, implementation approach, and capital efficient business models, in lieu of the technology alone.
Traditionally pharma's value proposition to society has been two dimensional - offering innovative medicines and (more recently) developing novel contracts to expand access to those medicines.
As new technological paradigms (e.g. AI/ML, IoT, Digital Medicines/Therapeutics, Digital Biomarkers) mature they are becoming integral to the value proposition of life science companies. These technologies are adding a third dimension to pharma's value proposition by transforming the medicine into an integrated solution which enables improved drug efficacy, better access, and enhanced care delivery.
At Reformulate we collaborate with pharma, medtech, biotech, digital health companies, and investors to identify and develop scalable solutions that enhance therapeutic area revenue growth opportunities across the drug value chain, using this third dimension.
We believe this third dimension is becoming the most potent driver of long-term healthcare value creation and impact, as it shifts the logic of the business.
by augmenting existing processes with a new generation of scalability-by-design digital core, digital UX and digital health solutions.
Augmenting well-established life sciences product development and commercialization strength with digital technology is far more difficult than had been anticipated. At Reformulate we work at the intersection of unconventional and obvious to bridge the gap between the established and the new in order to derive disproportional competitive advantages for your organization.
Often technology is not the key issue, but rather the culture, solution design, implementation approach and business model. We bridge this gap by collaborating with life science leaders, digital health companies, and investors to identify therapeutic area revenue growth opportunities, and put in place the strategy and capabilities that effectively manage innovation risk and accelerate the go-to-market timelines for a validated scalable solution.
Reformulate's portfolio approach combines the culture, people, strategy, go-to-market capabilities, and partnerships required to focus on the solution design, implementation approach, and capital efficient business models, in lieu of the technology alone.
Our customers today work with us to imagine, design and develop scalable digital solutions across drug discovery, drug-product commercialization, drug-product life cycle management, drug supply chain management, and beyond the molecule initiatives.
In this article our CEO Dr Ramin Rafiei explains how the convergence of conventional information technology & biotechnology is accelerating digital transformation across the drug value chain, and those that figure out how to harness it effectively will derive a disproportional competitive advantage.
In this JMIR publication Dr Ramin Rafiei and Dr Timothy Aungst measure the digital health maturity of the top 15 biopharmaceutical companies in the US biologics market and establish the framework for next-generation autoinjectable devices powering home-based precision care.